Neurocutaneous Disorders in Pregnancy.


Journal

Obstetrical & gynecological survey
ISSN: 1533-9866
Titre abrégé: Obstet Gynecol Surv
Pays: United States
ID NLM: 0401007

Informations de publication

Date de publication:
Oct 2023
Historique:
medline: 20 11 2023
pubmed: 17 11 2023
entrez: 17 11 2023
Statut: ppublish

Résumé

Neurocutaneous disorders have significant implications for care of the pregnant patient. As neurocutaneous disorders are uncommon, obstetricians may be unfamiliar with these disorders and with recommendations for appropriate care of this population. This review aims to summarize existing literature on the interaction between neurocutaneous disorders and pregnancy and to provide a guide for physicians caring for an affected patient. A PubMed, MEDLINE, and Google Scholar search was carried out with a broad range of combinations of the medical subject headings (MeSH) terms "pregnancy," "Sturge -Weber," "Neurofibromatosis Type 1," "neurofibromatosis type 2," "von Hippel Lindau," "Tuberous Sclerosis," "neurocutaneous disorder," "treatment," "congenital malformations," "neurodevelopmental defects," "miscarriage," "breastfeeding," "autoimmune," "pathophysiology," and "management." References of included articles were searched to identify any articles that may have been missed after the above method was used. Neurocutaneous disorders are associated with increased pregnancy-associated maternal and fetal/neonatal morbidity, largely surrounding hypertensive disorders, epilepsy, and medication exposure. Some features of neurocutaneous disorders may be worsened or accelerated by pregnancy. Neurocutaneous disorders can often be diagnosed prenatally. Therefore, directed assessment should be offered to affected individuals with a personal or family history of a neurocutaneous disorder. Patients affected by neurocutaneous disorders who are pregnant or planning for future pregnancy should be carefully followed by a multidisciplinary team, which could include maternal-fetal medicine, neurology, and anesthesia, as well as other relevant subspecialists. Additional research is required regarding optimal counseling and management of these patients.

Identifiants

pubmed: 37976316
doi: 10.1097/OGX.0000000000001202
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

606-619

Auteurs

Jay Idler (J)

Maternal Fetal Medicine Specialist, Allegheny Health Network, Pittsburgh, PA; Assistant Professor, Drexel College of Medicine, Philadelphia, PA.

Onur Turkoglu (O)

Maternal Fetal Medicine Fellow.

Kara Patek (K)

Maternal Fetal Medicine Fellow.

Sean Stuart (S)

Obstetrics and Gynecology Resident, William Beaumont University Hospital, Corewell Health, Royal Oak.

Birce Taskin (B)

Child Neurologist, Pediatric Neurology Department, Children's Hospital of Michigan, Wayne State University, Detroit.

Lalitha Sivaswamy (L)

Child Neurologist, Pediatric Neurology Department, Children's Hospital of Michigan, Wayne State University, Detroit.

Amy Whitten (A)

Maternal Fetal Medicine Fellow; Maternal Fetal Medicine Specialist and Associate Professor, William Beaumont University Hospital, Corewell Health, Royal Oak, MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH